S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
Log in

XOMA Stock Price, Forecast & Analysis (NASDAQ:XOMA)

$24.65
+0.96 (+4.05 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$23.44
Now: $24.65
$24.68
50-Day Range
$17.30
MA: $19.34
$24.00
52-Week Range
$11.02
Now: $24.65
$24.68
Volume67,005 shs
Average Volume58,470 shs
Market Capitalization$215.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.30 million
Book Value$2.24 per share

Profitability

Net Income$-13,340,000.00

Miscellaneous

Employees11
Market Cap$215.74 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.


XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) announced its earnings results on Tuesday, November, 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.68. The biotechnology company earned $8.86 million during the quarter. XOMA had a negative net margin of 10.19% and a negative return on equity of 8.93%. View XOMA's Earnings History.

When is XOMA's next earnings date?

XOMA is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for XOMA.

What price target have analysts set for XOMA?

2 equities research analysts have issued twelve-month price objectives for XOMA's stock. Their forecasts range from $25.00 to $30.00. On average, they expect XOMA's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for XOMA.

What is the consensus analysts' recommendation for XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.

What are Wall Street analysts saying about XOMA stock?

Here are some recent quotes from research analysts about XOMA stock:
  • 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (11/9/2019)
  • 2. HC Wainwright analysts commented, "We project U.S. peak sales of $325M in 2026 for DSUVIA. For Zalviso, we project product launch in 1H20 (85% POS) with peak sales in 2027 of about $185M. We apply a 12.5% discount rate to both products." (4/12/2019)

Has XOMA been receiving favorable news coverage?

Press coverage about XOMA stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XOMA earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for XOMA.

Are investors shorting XOMA?

XOMA saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 474,300 shares, a decrease of 7.7% from the August 30th total of 513,600 shares. Based on an average daily volume of 69,800 shares, the short-interest ratio is currently 6.8 days. Currently, 6.0% of the shares of the company are sold short. View XOMA's Current Options Chain.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the folowing people:
  • Mr. James R. Neal, CEO & Director (Age 63)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
  • Dr. Deepshikha Datta, Chief Bus. Officer

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $24.65.

How big of a company is XOMA?

XOMA has a market capitalization of $215.74 million and generates $5.30 million in revenue each year. The biotechnology company earns $-13,340,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. XOMA employs 11 workers across the globe.View Additional Information About XOMA.

What is XOMA's official website?

The official website for XOMA is http://www.xoma.com/.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]


MarketBeat Community Rating for XOMA (NASDAQ XOMA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  746
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel